Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Xi Hong

Showing results (211-220 of 216) with videos related to

Pageof 22
Sort By:
You have reached the last page of results.This site can display upto 216 results.
Biomedical and Environmental Sciences : BES|December 17, 2013
Molecular epidemiological characteristics of Streptococcus pyogenes strains involved in an outbreak of scarlet fever in China, 2011Yuan Hai You, Yan Yan Song, Xiao Mei Yan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 23, 2021
Trastuzumab Plus Endocrine Therapy or Chemotherapy as First-line Treatment for Patients with Hormone Receptor-Positive and HER2-Positive Metastatic Breast Cancer (SYSUCC-002)Xin Hua, Xi-Wen Bi, Jian-Li Zhao, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|September 11, 2024
Safety evaluation of extracorporeal shockwave lithotripsy for pancreatic stones: Experience based on a large chronic pancreatitis cohortYu Liu, Jin-Hui Yi, Peng-Yuan Wang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 2, 2025
Metronomic Capecitabine Plus Aromatase Inhibitor as Initial Therapy in Patients With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: The Phase III MECCA TrialRuo-Xi Hong, Fei Xu, Wen Xia, et al.
JAMA|December 10, 2020
Effect of Capecitabine Maintenance Therapy Using Lower Dosage and Higher Frequency vs Observation on Disease-Free Survival Among Patients With Early-Stage Triple-Negative Breast Cancer Who Had Received Standard Treatment: The SYSUCC-001 Randomized Clinical TrialXi Wang, Shu-Sen Wang, Heng Huang, et al.
Breast Cancer (Dove Medical Press)|April 17, 2024
Does the Dose of Standard Adjuvant Chemotherapy Affect the Triple-negative Breast Cancer Benefit from Extended Capecitabine Metronomic Therapy? An Exploratory Analysis of the SYSUCC-001 TrialYing Chen, Wen-Xia Li, Jia-Hua Wu, et al.
Pageof 22

Showing results (211-220 of 216) with videos related to

Sort By:
Pageof 22
You have reached the last page of results.This site can display upto 216 results.
Biomedical and Environmental Sciences : BES|December 17, 2013
Molecular epidemiological characteristics of Streptococcus pyogenes strains involved in an outbreak of scarlet fever in China, 2011Yuan Hai You, Yan Yan Song, Xiao Mei Yan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 23, 2021
Trastuzumab Plus Endocrine Therapy or Chemotherapy as First-line Treatment for Patients with Hormone Receptor-Positive and HER2-Positive Metastatic Breast Cancer (SYSUCC-002)Xin Hua, Xi-Wen Bi, Jian-Li Zhao, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|September 11, 2024
Safety evaluation of extracorporeal shockwave lithotripsy for pancreatic stones: Experience based on a large chronic pancreatitis cohortYu Liu, Jin-Hui Yi, Peng-Yuan Wang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 2, 2025
Metronomic Capecitabine Plus Aromatase Inhibitor as Initial Therapy in Patients With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: The Phase III MECCA TrialRuo-Xi Hong, Fei Xu, Wen Xia, et al.
JAMA|December 10, 2020
Effect of Capecitabine Maintenance Therapy Using Lower Dosage and Higher Frequency vs Observation on Disease-Free Survival Among Patients With Early-Stage Triple-Negative Breast Cancer Who Had Received Standard Treatment: The SYSUCC-001 Randomized Clinical TrialXi Wang, Shu-Sen Wang, Heng Huang, et al.
Breast Cancer (Dove Medical Press)|April 17, 2024
Does the Dose of Standard Adjuvant Chemotherapy Affect the Triple-negative Breast Cancer Benefit from Extended Capecitabine Metronomic Therapy? An Exploratory Analysis of the SYSUCC-001 TrialYing Chen, Wen-Xia Li, Jia-Hua Wu, et al.
Pageof 22